Tenofovir Disoproxil: 4 agencies, 2002–2020
This page collects every recorded health technology assessment decision for one molecule across the agencies in our archive, and compares them. The comparison is the point: each agency publishes its own verdict, none publishes how that verdict sits against the others.
What the record shows
AWMSG (Wales) has been easier on tenofovir disoproxil than on its own caseload: it refused 1 of 5 decisive submissions here (20%), against a base rate of 49% across everything it has assessed.
The file has been open for more than a decade: 17.8 years separate the first record, 14 Jun 2002 at SMC (Scotland), from the most recent, 20 Mar 2020 at HAS (France).
SMC (Scotland) changed its position: recommended on 12 Sep 2011, restricted by 9 Sep 2013.
Coverage is thin among the largest agencies: 5 of the eight highest-volume bodies — PBAC (Australia), PHARMAC (New Zealand) and TLV (Sweden) among them — hold no record for tenofovir disoproxil at all.
Nothing has been added since 2020; on this evidence the file is dormant.
The programme is broad: 10 distinct indication wordings are recorded for tenofovir disoproxil by the agencies that label one in English (AWMSG, NICE and SMC).
SMC (Scotland) was first to assess tenofovir disoproxil, on 14 Jun 2002; NICE (England) did not open a file until 22 Jul 2009 — a wide spread of 7.1 years between the earliest and latest system to look at it.
Activity is concentrated rather than steady: 8 of 19 dated records fall in 2013 alone.
Restriction is doing real work here: 3 of 12 decisive outcomes narrowed tenofovir disoproxil to a subgroup rather than accepting or refusing it outright, at SMC (Scotland).
3 of the 4 agencies here assessed tenofovir disoproxil more than once, AWMSG (Wales) most often at 7 entries — repeat review is the norm for this molecule rather than the exception.
Coverage is narrow: only 4 of the 18 agencies here have assessed tenofovir disoproxil.
The full ledger for tenofovir disoproxil reads 8 recommended, 5 other, 3 restricted and 1 not recommended, with 2 in other categories.
Decisions on file
| Agency | Date | Indication as recorded | Outcome | Source |
|---|---|---|---|---|
| HAS (France) | 20 Mar 2020 | Indication extension | SMR substantial · ASMR IV | source |
| AWMSG (Wales) | 18 Sep 2019 | For the treatment of hepatitis B in paediatric patients aged 6 to < 12 years with compensated liver disease and evidence… | not endorsed (non-submission) | source |
| AWMSG (Wales) | 8 May 2014 | Treatment of chronic hepatitis B in adults with evidence of lamivudine-resistant hepatitis B virus | recommended (limited) | source |
| SMC (Scotland) | 9 Sep 2013 | HIV-1 infection - in combination with other antiretroviral medicinal products for the treatment of human immunodeficiency virus (HIV 1) infected paediatric and adolescent… | accepted (restricted) | source |
| NICE (England) | 22 Jul 2009 | NICE TA173 | recommended | source |
14 further decisions for tenofovir disoproxil, across 3 agencies, are not shown here. They link to 10 further source documents.
Related molecules
- sofosbuvir — same ATC class J05A — Antivirals
- letermovir — same ATC class J05A — Antivirals
- raltegravir — same ATC class J05A — Antivirals
- cabotegravir — same ATC class J05A — Antivirals
- tenofovir — same ATC class J05A — Antivirals
- darunavir — same ATC class J05A — Antivirals
Coverage: 19 decisions for tenofovir disoproxil from 4 agencies, 2002 to 2020. Data to 7 Sep 2026. ATC class J05A — Antivirals. How this page is produced. Compiled by Altima Partners; queries: sales@altimapartners.co.uk.